Clene stock touches 52-week low at $2.5 amid market challenges

Clene Inc. (CLNN) has hit a 52-week low of $2.5, reflecting a 64.31% stock price decline over the past year amid negative EBITDA and cash burn concerns. Despite reporting disappointing EPS figures for Q4 2024 and FY2024, the company highlighted positive findings from its VISIONARY-MS Trial extension study and secured financing through an equity distribution agreement; H.C. Wainwright maintains a Buy rating with a $31 price target based on CNM-Au8's potential in ALS trials and ongoing FDA discussions.

Analysis

Clene Inc. (CLNN) is navigating a challenging period, underscored by its common stock reaching a 52-week low of $2.50 and a significant 64.31% decline over the past year, bringing its market capitalization to $23.36 million. The company's financial position is strained, evidenced by a negative EBITDA of -$26.31 million, rapid cash consumption, and anticipated sales decline, as highlighted by InvestingPro analysis. Fourth-quarter 2024 earnings per share of ($1.61) and full-year 2024 EPS of ($5.67) both missed analyst expectations. Clene ended 2024 with $12.2 million in cash, projected to fund operations only until the second quarter of 2025, highlighting near-term funding pressures. Despite these financial headwinds, the company reported positive clinical developments, including significant findings from its VISIONARY-MS trial extension study for CNM-Au8, suggesting potential neuronal repair and remyelination. Furthermore, promising results from CNM-Au8 in ALS trials are supporting ongoing discussions with the FDA for potential accelerated approval, with a Phase 3 RESTORE-ALS study planned for mid-2025. To manage its finances, Clene resolved a $125,000 debt by issuing 35,311 shares at $3.54 each and entered an equity distribution agreement with Canaccord Genuity LLC to potentially raise up to $25 million. H.C. Wainwright maintains a Buy rating and a $31 price target, primarily driven by the prospects of CNM-Au8.

Key Decisions for Investors

• Investors should carefully weigh the substantial clinical potential of CNM-Au8 against Clene's precarious financial situation, particularly its limited cash runway until Q2 2025 and ongoing cash burn.
• Close monitoring of the company's progress in FDA discussions for CNM-Au8 and key milestones from the upcoming Phase 3 RESTORE-ALS study is crucial, as these represent significant potential catalysts or risk factors.
• Consideration must be given to the potential dilutive impact on existing shareholdings from the $25 million equity distribution agreement and the recent debt-to-equity conversion.